Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

摘要

Correction to : British Journal of Cancer (2019) 120 , 183–189; 10.1038/s41416-018-0343-z; published online 11 December 2018 The original version of this article contained an error in Fig.? 1a . The number of patients at risk listed in the Veliparib arm of Fig.? 1a should have read “65” instead of “35”. The correct figure is below. Fig. 1 a Progression-free survival at final analysis and b overall survival at final analysis. CI confidence interval, PBO placebo?+?FOLFIRI?±?bevacizumab, VEL veliparib?+?FOLFIRI?±?bevacizumab